Skip to content
CancerIndex

Publication

Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia.

Authors not recorded

Nat Commun2016PMID 27824051PMC5105166stubpubmedProvenance
Source
PubMed
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-CIVIC-20260908-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (2)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 2

Curated evidence

Evidence citing this paper (4)

civicProvenance
Source
CIViC — Clinical Interpretation of Variants in Cancer
Dataset
CIViC evidence items
Version
civic-2026-09-08
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Evidence
expert curation
License
CC0 1.0
PMID
27824051
Run
ING-CIVIC-20260908-000001
Open at source CuratedShowing 1–4 of 4 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.
TherapyCancerTypeLevelDirection · significanceRating (1–5)StatusEvidenceSource
MEF2D MEF2D Rearrangement1
(prognostic)B Acute Lymphoblastic LeukemiaALIASPrognosticBSupports Poor Outcome4submitted
EID8624

MEF2D encodes myocyte enhancer factor 2D and is mapped to chromosome 1q21–22. It is expressed throughout B-cell differentiation and inactivation of Mef2c/d results in an arrest in B-lymphoid maturatio… (full text at CIViC)

PMID 27824051 · Gu et al., 2016 · Open in CIViC

civic
CSF1R Fusion1
PanobinostatB Lymphoblastic Leukemia/LymphomaCURATED_BROADERPredictiveDSupports Sensitivity Response3submitted
EID9359

In this study, 560 cases of B-ALL were analyzed by RNAseq, 22 (3.9%) of which (3.9%) demonstrated rearrangements of MEF2D at chromosome 1q21–22, encoding myocyte enhancer factor 2D, representing 15 of… (full text at CIViC)

PMID 27824051 · Gu et al., 2016 · Open in CIViC

civic
ABL2 Fusion1
(oncogenic)B Lymphoblastic Leukemia/LymphomaCURATED_BROADEROncogenicCSupports Oncogenicity3submitted
EID9769

In a study of Transcriptome sequencing to identify fusions and mutations on 560 ALL Patients enrolled on a multi-center Alliance, two patients were identified to carry the RCSD1-ABL2 fusion. One was a… (full text at CIViC)

PMID 27824051 · Gu et al., 2016 · Open in CIViC

civic
MEF2D Fusion1
(diagnostic)B-lymphoblastic Leukemia With MEF2D RearrangementUNRESOLVEDDiagnosticBSupports Positive4accepted
EID12199

The paper explores the diagnostic significance of MEF2D gene fusions in B-lymphoblastic leukemia (B-ALL), identifying them as important markers for a specific subgroup of the disease. RNA sequencing o… (full text at CIViC)

PMID 27824051 · Gu et al., 2016 · Open in CIViC

civic